Decheng Capital Management III (Cayman)’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50,000	Closed	-$92.5K	–	27
2023 Q2	$92.5K	Hold	50,000	–	–	0.03%	25
2023 Q1	$185K	Hold	50,000	–	–	0.07%	24
2022 Q4	$190K	Hold	50,000	–	–	0.07%	26
2022 Q3	$395K	Hold	50,000	–	–	0.14%	26
2022 Q2	$1.05M	Hold	50,000	–	–	0.4%	21
2022 Q1	$1.88M	Buy	+50,000	New	+$1.73M	0.58%	21

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s NBSE Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2023, closing a stake of 50,000 shares — an estimated $92.5K sold.

Decheng Capital Management III (Cayman) first reported a position in NBSE in Q1 2022 and held it in 6 quarters. The position peaked at $1.88M in Q1 2022. 21 funds tracked by Wall St. Rank hold NBSE as of Q3 2023.

Decheng Capital Management III (Cayman) reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Decheng Capital Management III (Cayman) sold 50,000 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $92.5K.
Decheng Capital Management III (Cayman) first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Decheng Capital Management III (Cayman)'s NeuBase Therapeutics, Inc. Common Stock position peaked at $1.88M in Q1 2022.
21 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.